Skip to content

UroGen Pharma URGN Finance Lease Liabilities

Finance Lease Liabilities at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$213K

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's finance lease liabilities?
UroGen Pharma (URGN) reported finance lease liabilities of $3.16M in Q1 2026.
How has UroGen Pharma's finance lease liabilities changed year-over-year?
UroGen Pharma's finance lease liabilities increased by 11.4% year-over-year, from $2.84M to $3.16M.
What is the long-term trend for UroGen Pharma's finance lease liabilities?
Over 2 years (2023 to 2025), UroGen Pharma's finance lease liabilities has grown at a 102.9% compound annual growth rate (CAGR), from $844K to $3.48M.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.